Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that Texas Prostate, led by Dr. James Cochran, has achieved its 100th TULSA Procedure™ performed in Dallas Medical Center's state-of-the-art MRI suite.

Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Profound Medical Corp. (PRN:CA) Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer Transcript

– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment –

Profound Medical Corp. (PRN:CA) Q4 2025 Earnings Call Transcript

Profound Medical (PROF) came out with a quarterly loss of $0.27 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.2 per share a year ago.

Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.